- Home
- ECX vs ZURA Comparison
ECX vs ZURA Comparison
Compare ECX & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECX | ZURA |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | United Kingdom | United States |
| Employees | 1432 | 40 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.7M | 455.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ECX | ZURA |
|---|---|---|
| Price | $1.17 | $5.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.0M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $819.14 | N/A |
| Revenue Next Year | $32.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $1.00 |
| 52 Week High | $2.70 | $7.25 |
Technical Indicators
Market Signals| Indicator | ECX | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 68.76 |
| Support Level | $1.05 | $4.36 |
| Resistance Level | $1.28 | $5.82 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 51.35 | 93.84 |
Price Performance
Historical ComparisonAbout ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the Peoples Republic of China. The companies core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.